Can a tiny eye implant replace glaucoma drops?

NCT ID NCT07754201

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests a new device called VividFlo, a small implant placed under the eye's surface to help drain fluid and lower pressure in people with glaucoma. The study involves 10 adults with glaucoma in one eye, who will receive the implant during surgery. Researchers will track eye pressure, the need for pressure-lowering medications, and any safety issues over 12 months. The goal is to see if this implant can safely and effectively control eye pressure and potentially reduce the need for daily eye drops.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VividFlo System (a subconjunctival glaucoma implant placed in the eye using a partial-thickness scleral flap technique)
What this could lead to
If successful, this could offer a new surgical option for glaucoma patients to lower eye pressure and reduce reliance on daily eye drops.
What could go wrong
This is a very small early study (10 people) focused on safety and feasibility. The implant may not lower pressure enough, or could cause complications like erosion or vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC ANGLE CLOSURE GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Melbourne Eye Specialists

    Fitzroy, Victoria, 3065, Australia

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.